Silexion Therapeutics Corp announced the successful dosing of the first patient in its global Phase 2/3 clinical trial for SIL204, a second-generation small interfering RNA therapy targeting KRAS-driven locally advanced pancreatic cancer. The study employs an integrated regimen combining EUS-guided intratumoral delivery with subcutaneous injections alongside standard chemotherapy. The trial structure includes an initial safety run-in cohort of approximately 18 patients followed by a randomized expansion cohort of roughly 166 participants. Dosing commenced at Tel Aviv Sourasky Medical Center, with additional sites in Israel and Germany expected to activate soon. Silexion Therapeutics Corp is a clinical-stage biotechnology company developing RNA interference therapies for KRAS-driven solid tumors.
